Literature DB >> 19532059

Global epidemiology of HIV.

Peter H Kilmarx1.   

Abstract

PURPOSE OF REVIEW: To provide an update on the epidemiology of HIV worldwide and by region, along with an overview of recent HIV epidemiological research. RECENT
FINDINGS: The global prevalence of HIV-1 has stabilized at 0.8%, with 33 million people living with HIV/AIDS, 2.7 million new infections, and 2.0 million AIDS deaths in 2007. Heterosexual spread in the general population is the main mode of transmission in sub-Saharan Africa, which remains the most heavily affected region, with 67% of the global burden. Male-male sex, injection drug use, and sex work are the predominant risk factors in most other regions. Infection rates are declining in some regions, including some of the most heavily affected countries in Africa, but climbing elsewhere such as in eastern Europe and central Asia. Recent HIV epidemiologic research findings include new insights into the role of HIV viral load, co-infection with sexually transmitted infections, male circumcision, antiretroviral treatment, serosorting, and superinfection in HIV transmission and prevention.
SUMMARY: The global prevalence of HIV has stabilized in this decade, but with important regional differences in trends and modes of transmission. Prevention and treatment programs have an expanding impact in preventing HIV infection and AIDS deaths.

Entities:  

Mesh:

Year:  2009        PMID: 19532059     DOI: 10.1097/COH.0b013e32832c06db

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  53 in total

1.  Anti-AIDS agents 79. Design, synthesis, molecular modeling and structure-activity relationships of novel dicamphanoyl-2',2'-dimethyldihydropyranochromone (DCP) analogs as potent anti-HIV agents.

Authors:  Ting Zhou; Qian Shi; Chin-Ho Chen; Hao Zhu; Li Huang; Phong Ho; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem       Date:  2010-08-02       Impact factor: 3.641

2.  Sexual orientation and mortality among US men aged 17 to 59 years: results from the National Health and Nutrition Examination Survey III.

Authors:  Susan D Cochran; Vickie M Mays
Journal:  Am J Public Health       Date:  2011-04-14       Impact factor: 9.308

Review 3.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

4.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Authors:  Pedro Rodríguez Quesada; Laura López Esteban; Jimena Ramón García; Rocío Vázquez Sánchez; Teresa Molina García; Gabriel Gaspar Alonso-Vega; Javier Sánchez-Rubio Ferrández
Journal:  Int J Clin Pharm       Date:  2015-05-26

5.  Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

Authors:  David S Metzger; Deborah Donnell; David D Celentano; J Brooks Jackson; Yiming Shao; Apinun Aramrattana; Liu Wei; Liping Fu; Jun Ma; Gregory M Lucas; Marek Chawarski; Yuhua Ruan; Paul Richardson; Katherine Shin; Ray Y Chen; Jeremy Sugarman; Bonnie J Dye; Scott M Rose; Geetha Beauchamp; David N Burns
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

6.  Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Authors:  Joseph A Fraietta; Yvonne M Mueller; Duc H Do; Veronica M Holmes; Mary K Howett; Mark G Lewis; Alina C Boesteanu; Sefik S Alkan; Peter D Katsikis
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

7.  Prediction of the interaction of HIV-1 integrase and its dicaffeoylquinic acid inhibitor through molecular modeling approach.

Authors:  Zengjian Hu; Dagang Chen; Lanxiang Dong; W M Southerland
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

8.  Diverse peptide presentation of rhesus macaque major histocompatibility complex class I Mamu-A 02 revealed by two peptide complex structures and insights into immune escape of simian immunodeficiency virus.

Authors:  Jun Liu; Lianpan Dai; Jianxun Qi; Feng Gao; Youjun Feng; Wenjun Liu; Jinghua Yan; George F Gao
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

9.  Anti-AIDS agents 86. Synthesis and anti-HIV evaluation of 2',3'-seco-3'-nor DCP and DCK analogues.

Authors:  Ying Chen; Ming Cheng; Fa-Qiang Liu; Peng Xia; Keduo Qian; Donglei Yu; Yi Xia; Zheng-Yu Yang; Chin-Ho Chen; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Eur J Med Chem       Date:  2011-08-04       Impact factor: 6.514

10.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.